Unknown

Dataset Information

0

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.


ABSTRACT: We investigated the predictive value of dihydropyrimidine dehydrogenase (DPD) phenotype, measured as pretreatment serum uracil and dihydrouracil concentrations, for severe as well as fatal fluoropyrimidine-associated toxicity in 550 patients treated previously with fluoropyrimidines during a prospective multicenter study.Pretreatment serum concentrations of uracil and dihydrouracil were measured using a validated LC-MS/MS method. The primary endpoint of this analysis was global (any) severe fluoropyrimidine-associated toxicity, that is, grade ?3 toxicity according to the NCI CTC-AE v3.0, occurring during the first cycle of treatment. The predictive value of uracil and the uracil/dihydrouracil ratio for early severe fluoropyrimidine-associated toxicity were compared. Pharmacogenetic variants in DPYD (c.2846A>T, c.1679T>G, c.1129-5923C>G, and c.1601G>A) and TYMS (TYMS 5'-UTR VNTR and TYMS 3'-UTR 6-bp ins/del) were measured and tested for associations with severe fluoropyrimidine-associated toxicity to compare predictive value with DPD phenotype. The Benjamini-Hochberg false discovery rate method was used to control for type I errors at level q<0.050 (corresponding to P<0.010).Uracil was superior to the dihydrouracil/uracil ratio as a predictor of severe toxicity. High pretreatment uracil concentrations (>16?ng?ml-1) were strongly associated with global severe toxicity (OR 5.3, P=0.009), severe gastrointestinal toxicity (OR 33.7, P<0.0001), toxicity-related hospitalisation (OR 16.9, P<0.0001), as well as fatal treatment-related toxicity (OR 44.8, P=0.001). None of the DPYD variants alone, or TYMS variants alone, were associated with severe toxicity.High pretreatment uracil concentration was strongly predictive of severe, including fatal, fluoropyrimidine-associated toxicity, and is a highly promising phenotypic marker to identify patients at risk of severe fluoropyrimidine-associated toxicity.

SUBMITTER: Meulendijks D 

PROVIDER: S-EPMC5520099 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7564232 | BioStudies
2017-01-01 | S-EPMC5421769 | BioStudies
1000-01-01 | S-EPMC6313617 | BioStudies
2020-01-01 | S-EPMC7368113 | BioStudies
2014-01-01 | S-EPMC4071869 | BioStudies
2015-01-01 | S-EPMC4425114 | BioStudies
2019-01-01 | S-EPMC6258870 | BioStudies
2019-01-01 | S-EPMC6474277 | BioStudies
2018-01-01 | S-EPMC6066555 | BioStudies
2019-01-01 | S-EPMC6533219 | BioStudies